J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's successful bid to acquire Pfizer Consumer Healthcare extends the firm's reach in the global OTC market and provides entry into several new product categories
You may also be interested in...
Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey
Drug companies offering smoking-cessation products could stoke their sales by marketing to U.S. businesses, results of a Pfizer-sponsored survey show
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
EC eyes J&J-Pfizer
The European Commission says it will decide by Nov. 27 whether to sign off on Johnson & Johnson's proposed acquisition of Pfizer Consumer Healthcare or to open a full-scale investigation in a process that could last three months. The EC's Competition Directorate will accept comments on the proposed deal until 10 calendar days from the date it announced its preliminary review, Oct. 26. J&J proposes paying $16.6 bil. for Pfizer's OTC brands, including Nicorette and Sudafed (1"The Tan Sheet" July 3, 2006, p. 3). To facilitate the deal's completion, J&J already has agreed to sell its OTC Zantac heartburn medication to Boehringer for $509 mil. (2"The Tan Sheet" Oct. 16, 2006, p. 9)...